Cancer Immunotherapy: IMPRESS Study
The Programmed Death 1 (PD-1) pathway plays a critical role in many malignancies. To date, the Food and Drug Administration has approved several anti-PD-1 and anti-PD-1 ligand (anti-PD-L1) treatments based on data that provides renewed hope for the effective treatment of cancer even in advanced cases, but the clinical outcomes with immune checkpoint agents have been variable.
Currently, there is no method to reliably predict an individual patient's likelihood of benefit from immunotherapy, or to monitor an individual's response once treatment begins. The Immunotherapy With Precision Biomarkers (IMPRESS) Study evaluates the likelihood of patients benefiting from immunotherapy to maximize the benefit and minimize the risk of side effects from immune-based treatments as part of the standard of care.
The IMPRESS Study involved the collection of participant biospecimens for the evaluation of internally developed assays designed to predict and monitor patient responses to currently available PD-1 and PD-L1 inhibitors. Participants also had the opportunity to obtain clinical-level sequencing results from tumor biopsies through the Center for Individualized Medicine's collaboration with Tempus, a technology company focused on facilitating personalized cancer care.
A total of 200 Mayo Clinic patients were recruited to the IMPRESS Study. Participants were followed at time points relevant to the initiation of therapy with PD-1/PD-L1 directed therapy. The goal was to optimize two models: A blood- and tissue-based model and a blood-based model to accommodate patients for whom there is no available tumor tissue for biomarker assessment.
Contact IMPRESS study team members for more information:
You can also contact the Center for Individualized Medicine for information on clinical studies and trials.